Lipoedema is characterized by disproportionate limb fat, frequently misidentified as obesity or lymphoedema. A review examined the metabolic phenotype of lipoedema and its implications for cardiometabolic assessment. The search encompassed studies on lipoedema, obesity, body composition, metabolic risk, insulin resistance, diabetes, lifestyle interventions, pharmacotherapy, and liposuction, utilizing PubMed/MEDLINE data from its inception through May 2026.
Metabolic Phenotype and Risk Assessment
Observations indicate that women with lipoedema may exhibit fewer metabolic abnormalities compared to women with BMI-matched lifestyle-related overweight or obesity. However, this does not establish metabolic protection. Differences may be attributed to variations in central adiposity, disease stage, diagnostic criteria, body composition, inflammation, or referral patterns. Obesity and glucose-lowering therapies remain appropriate for established indications. Direct modification of lipoedema has not been demonstrated. Cardiometabolic risk assessment in lipoedema requires a phenotype-based approach, differentiating painful limb adiposity from central and ectopic fat. This approach should incorporate factors such as age, sex, menopausal status, and established risk factors.
Future Research Directions
Further research, including prospective studies with standardized criteria and direct measures of insulin sensitivity, is needed to clarify long-term risk and to differentiate lipoedema biology from coexisting central obesity.